Compare TransMedics Group Inc (TMDX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs ProShares Ultra Gold ETF — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M). The key difference: TransMedics Group Inc is far larger — about 3.8× ProShares Ultra Gold ETF's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 2,592,878). Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and ProShares Ultra Gold ETF for 23 Days on average.
| TMDX | UGL | |
|---|---|---|
Market Cap | $2.74B | $716.59M |
Volume | 949,331 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $150.42 | $85.62 |
52-Week Low | $61.99 | $42.79 |
Typical Hold Time | 24 Days | 23 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
UGL is trading at $46.45, up 4.55% today, but faces significant technical headwinds with a bearish overall signal. The stock shows neutral momentum oscillators but bearish moving averages, with key resistance at $46. Current financial ratios are unavailable, limiting fundamental assessment. Recent gold market volatility driven by Treasury yields and Fed policy expectations creates uncertainty for gold-related equities.
The outlook remains cautious given technical weakness and macroeconomic pressures on gold prices. Investment opportunity exists for contrarian investors if gold regains momentum, but risks include persistent rate hike expectations and dollar strength. Stock-specific fundamentals require verification through SEC filings for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
